Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of AMG 827 in Rheumatoid Arthritis
2009-016119-38Phase 2Terminated
- Sponsor
- Amgen
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brodalumab in rheumatoid arthritis (RA), sponsored by Amgen. Primary endpoint: Adverse events. Started Mar 2010; status: terminated.
02
Drugs
brodalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-016119-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016119-38.